Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

熊去氧胆酸 医学 内科学 安慰剂 胃肠病学 双盲 兴奋剂 药理学 受体 病理 化学 替代医学
作者
David Jones,Pol Boudes,Mark G. Swain,Christopher L. Bowlus,Michael Galambos,Bruce R. Bacon,Yvonne Döerffel,Norman Gitlin,Stuart C. Gordon,Joseph A. Odin,David Sheridan,M A Wörns,Virginia Clark,Linsey Corless,Heinz Hartmann,Mark Jonas,Andreas E. Kremer,George Mells,Peter Buggisch,B. Freilich
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:2 (10): 716-726 被引量:185
标识
DOI:10.1016/s2468-1253(17)30246-7
摘要

Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid. Seladelpar is a potent, selective agonist for the peroxisome proliferator-activated receptor-delta (PPAR-δ), which is implicated in bile acid homoeostasis. This first-in-class study evaluated the anti-cholestatic effects and safety of seladelpar in patients with an inadequate response to ursodeoxycholic acid.The study was a 12-week, double-blind, placebo-controlled, phase 2 trial of patients with alkaline phosphatase of at least 1·67 times the upper limit of normal (ULN) despite treatment with ursodeoxycholic acid. Patients, recruited at 29 sites in North America and Europe, were randomly assigned to placebo, seladelpar 50 mg/day, or seladelpar 200 mg/day while ursodeoxycholic acid was continued. Randomisation was done centrally (1:1:1) by a computerised system using an interactive voice-web response system with a block size of three. Randomisation was stratified by region (North America and Europe). The primary outcome was the percentage change from baseline in alkaline phosphatase over 12 weeks, analysed in the modified intention-to-treat (ITT) population (any randomised patient who received at least one dose of medication and had at least one post-baseline alkaline phosphatase evaluation). This study is registered with ClinicalTrials.gov (NCT02609048) and the EU Clinical Trials Registry (EudraCT2015-002698-39).Between Nov 4, 2015, and May 26, 2016, 70 patients were screened at 29 sites in North America and Europe. During recruitment, three patients treated with seladelpar developed fully reversible, asymptomatic grade 3 alanine aminotransferase increases (one on 50 mg, two on 200 mg), ranging from just over five to 20 times the ULN; as a result, the study was terminated after 41 patients were randomly assigned. The modified ITT population consisted of 12 patients in the placebo group, 13 in the seladelpar 50 mg group, and 10 in the seladelpar 200 mg group. Mean changes from baseline in alkaline phosphatase were -2% (SD 16) in the placebo group, -53% (14) in the seladelpar 50 mg group, and -63% (8) in the seladelpar 200 mg group. Changes in both seladelpar groups versus placebo were significant (p<0·0001 for both groups vs placebo), with no significant difference between the two seladelpar groups (p=0·1729). All five patients who received seladelpar for 12 weeks had normal alkaline phosphatase values at the end of treatment, based on a central laboratory ULN for alkaline phosphatase of 116 U/L. The most frequently reported adverse events were pruritus (16%; one patient on placebo, four on seladelpar 50 mg, and one on seladelpar 200 mg), nausea (13%; one patient on placebo, three on seladelpar 50 mg, and one on seladelpar 200 mg), diarrhoea (10%; two patients on placebo, one on seladelpar 50 mg, and one on seladelpar 200 mg), dyspepsia (8%; two patients on seladelpar 50 mg and one on seladelpar 200 mg), muscle spasms (8%; three patients on seladelpar 200 mg), myalgia (8%; one patient on placebo and two on seladelpar 200 mg), and dizziness (8%; one patient on placebo and two on seladelpar 50 mg).Seladelpar normalised alkaline phosphatase levels in patients who completed 12 weeks of treatment. However, treatment was associated with grade 3 increases in aminotransferases and the study was stopped early. The effects of seladelpar should be explored at lower doses.CymaBay Therapeutics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wqy完成签到,获得积分10
刚刚
充电宝的应助被阿坤采纳,获得10
刚刚
1秒前
1秒前
1秒前
1秒前
谢美阳阳完成签到,获得积分10
1秒前
先锋老刘001完成签到,获得积分10
1秒前
李李完成签到,获得积分10
2秒前
2秒前
顾矜的应助被wfc采纳,获得10
2秒前
喵呜啦啦啦啦完成签到,获得积分10
3秒前
3秒前
3秒前
Monicadd完成签到 ,获得积分10
5秒前
CITY111119发布了新的文献求助50
5秒前
min发布了新的文献求助10
5秒前
AJKLDJAK发布了新的文献求助10
6秒前
6秒前
Imagine发布了新的文献求助10
6秒前
何雨航发布了新的文献求助10
6秒前
panzerVI完成签到,获得积分10
6秒前
果子完成签到,获得积分20
6秒前
7秒前
7秒前
8秒前
8秒前
9秒前
茉云完成签到,获得积分10
9秒前
10秒前
晚霞跌落星河的应助被MADAO采纳,获得30
10秒前
小珂完成签到,获得积分10
11秒前
FossilGitter8发布了新的文献求助10
11秒前
英姑的应助被酷酷的冬灵采纳,获得50
11秒前
受伤白安发布了新的文献求助10
12秒前
cosscant发布了新的文献求助10
12秒前
春天完成签到 ,获得积分10
13秒前
13秒前
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182014
求助须知:如何正确求助?哪些是违规求助? 9571728
关于积分的说明 21819478
捐赠科研通 7778441
什么是DOI,文献DOI怎么找? 3433580
关于科研通互助平台的介绍 2557781
邀请新用户注册赠送积分活动 2479640